Positive Opinion on OMPD for NTI164 in Europe
Filed with ASX · · 2 pages · English
Neurotech International Ltd. on 6ix
Earlier from Neurotech International
- NTI Signs Development Agreement for Cannabinoid Therapies
- Neurotech Receives $2.44 Million R&D Tax Incentive Refund
- Neurotech Receives US ODD in Rett Syndrome
- NTI Receives Ethics Approval to Commence Human PK Study
- Positive Genomic Effects of NTI164 in PANDAS/PANS Patients
Later from Neurotech International
- Appendix 4D and Half Year Accounts
- NTI164 Preclinical Toxicology Studies Update
- Positive Human PK Study Results for NTI164
- Appendix 4E & Annual Report to shareholders
- US FDA Rare Pediatric Disease Designation in Rett syndrome
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International